MInimal residual Disease Adapted Strategy / IFM 2020-02: frontline therapy for patients eligible for autologous stem cell transplantation less than 66 years; a prospective study from the French cooperative group IFM
This important study, named MInimal residual Disease Adapted Strategy / IFM 2020-02, is focused on treating multiple myeloma in individuals under 66 who might be eligible for a stem cell transplant. It's a Phase III trial, meaning it's comparing new treatment strategies to standard ones to see which is more effective and safer. The main goal is to find out if specific combinations of medications, like Kyprolis, Revlimid, Iberdomide, and Sarclisa, can lead to a state where very few cancer cells remain in the body – a condition called 'minimal residual disease' (MRD) negativity. Researchers hope these new approaches will improve long-term outcomes for patients by reducing the amount of cancer in their bodies more effectively before maintenance therapy.
At a glance
What is this study about?
This study is all about finding better ways to treat multiple myeloma, which is a cancer that affects certain cells in your bone marrow. It's for people under 66 years old who are generally well enough to have a type of treatment called an 'autologous stem cell transplant' – this is where your own healthy stem cells are given back to you after high-dose chemotherapy. The study is split into different parts, and each part compares two different treatment plans using various medications.
Researchers want to see if one treatment plan is better than another at getting rid of almost all the cancer cells in your body before you start a long-term 'maintenance' treatment. This state, where the amount of cancer is incredibly low, is called 'minimal residual disease (MRD) negativity.' Achieving MRD negativity is often a good sign for patients. The study is looking very closely at whether these new treatment combinations can achieve this more often and for longer periods than current approaches.
Ultimately, by carefully comparing these different treatment strategies, the study hopes to discover which ones are most effective at reducing the cancer and potentially improving how long people live without their cancer growing or coming back. This could lead to new, more personalised treatment options for people with multiple myeloma in the future.
Key takeaways
- This study is for people under 66 with multiple myeloma who may have a stem cell transplant.
- It tests new combinations of drugs to see which best reduces cancer cells to very low levels.
- The main goal is to improve long-term outcomes by achieving 'minimal residual disease' negativity.
- Participation involves taking experimental medications and regular medical check-ups.
- You will be closely monitored for both benefits and side effects of the treatments.
Who may be eligible?
This study is looking for both men and women to take part, specifically adults aged 18 and older. There isn't an upper age limit mentioned, but the study is designed for people who are under 66 years old.
To be considered, you must have multiple myeloma and be stable enough to potentially receive an autologous stem cell transplant. This means you're generally in good health apart from your cancer and meet certain medical criteria.
It's important to discuss with your doctor whether you meet all the specific requirements for this study, as there will be detailed medical checks to make sure the study is a good fit for you.
- Are you 18 years old or older?
- Are you under the age of 66?
- Have you been diagnosed with multiple myeloma?
- Are you generally well enough to be considered for an autologous stem cell transplant?
- Are you able to attend regular hospital appointments for tests and treatment?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you join this study, you'll be assigned to one of several treatment groups. This will involve taking different combinations of medications, which could include drugs like Kyprolis, Revlimid, Iberdomide, or Sarclisa, as well as steroids like Neofordex or Dectancyl. These medications will be given either as infusions (into a vein) or as capsules/tablets.
You'll have regular appointments for blood tests, physical exams, and other medical assessments to check how you're responding to treatment and to monitor for any side effects. The main goal will be to see if your cancer reaches a state of 'minimal residual disease negativity' before you move into a maintenance phase. The study will also track your health and cancer status for several years to see the long-term effects of the treatments. The exact schedule and duration of visits will depend on the specific treatment plan you receive and how your body responds.
Potential risks and benefits
Locations (2)
- —Belgium
- —France
Common questions
What is 'minimal residual disease'?
Minimal residual disease (MRD) means that tests can't find any cancer cells in your body, even with very sensitive methods. It doesn't mean you're cured, but it's a good sign that your treatment has been very effective.
What is a 'Phase III' study?
A Phase III study is a large-scale research project that compares a new treatment or approach to the best existing one. It's often the last step before a new treatment can be approved and made available to more people.
What is an 'autologous stem cell transplant'?
This is a treatment where your own healthy stem cells are collected and stored. You then receive high-dose chemotherapy to kill cancer cells, and after that, your stored stem cells are given back to you to help your body recover.
Will I know which treatment I'm getting?
In some parts of the study, you might not know which specific treatment plan you're on to ensure fair comparison. However, your doctors and the study team will always know and can answer your questions.
What are the main medications being tested?
The study is testing combinations of several drugs, including Kyprolis, Revlimid, Iberdomide, and Sarclisa, alongside other supportive medications like steroids.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.